Lineage Cell Therapeutics (LCTX) Payables (2010 - 2026)

Lineage Cell Therapeutics has reported Payables for 17 years, with the latest figure at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 68.04% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (down 68.04% YoY), and the FY2025 full-year result was $7.2 million, up 32.08% from the prior year.
• Payables for Q1 2026 stood at $1.6 million, down from $7.2 million in the prior quarter.
• The five-year high for Payables was $9.8 million in Q3 2022, with the low at $1.5 million in Q2 2025.
• Historically, Payables has averaged $4.6 million across 5 years, with a median of $4.7 million in 2023.
• Annual changes were most pronounced in 2022 — Payables surged 219.26% — and 2023, when it slumped 75.22%.
• Lineage Cell Therapeutics' Payables stood at $8.6 million in 2022, then declined by 27.16% to $6.3 million in 2023, then retreated by 13.29% to $5.4 million in 2024, then soared by 32.08% to $7.2 million in 2025, then plunged by 77.84% to $1.6 million in 2026.
• The last three Payables figures came in at $1.6 million (Q1 2026), $7.2 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.